CD274 and glioblastoma: 2) In checkpoint-resistant tumors (e.g., prostate, glioblastoma, TNBC), PTM-specific inhibitors or PROTAC-based degraders may re-sensitize tumors by downregulating PD-L1, IDO1, and immunosuppressive myeloid populations.